ReviewFrontiers in cell and developmental biology2026
Genetic loci responsible for atrioventricular block in children.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrioventricular block (AVB) represents a prevalent form of bradyarrhythmia in the pediatric population, broadly classified into congenital and acquired subtypes. Historically, the underlying mechanisms of AVB were predominantly attributed to structural cardiac anomalies, maternal autoantibody-mediated inflammatory processes, and pharmacological agents; however, the contribution of genetic factors remained largely underexplored. With the advent and progressive refinement of genetic sequencing technologies, a growing repertoire of arrhythmia-associated genes has been systematically identified. In this review, we comprehensively examine the genetic determinants implicated in pediatric AVB, encompassing genes encoding cardiac ion channels, including SCN5A, KCNQ1/KCNJ2 (KCN family), KCNH2 (HERG), TRPM4, and HCN4, as well as genes governing cardiac structural integrity (GJA5/GJA1, ZO-1, NKX2-5, TBX3/TBX5, HAND1/HAND2, and ID family members), metabolic regulation (PRKAG2, PPARA, and LAMP2), and immune-mediated pathways (TRIM21/TROVE2 and HLA class II loci). The genetic architecture underlying pediatric AVB demonstrates considerable complexity, characterized by notable genotypic heterogeneity and "multi-phenotypic" expressivity, wherein distinct mutations within a single gene may manifest across a spectrum of clinical phenotypes. Collectively, these findings establish a molecular framework for elucidating the pathogenesis of AVB, while simultaneously offering valuable insights to inform clinical diagnosis, facilitate precision-based intervention strategies, and guide the development of targeted therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.